مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

video

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

sound

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Persian Version

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

View:

358
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Download:

166
مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Cites:

Information Journal Paper

Title

RENOPROTECTION BY TELMISARTAN VERSUS BENAZEPRIL IN STREPTOZOTOCIN INDUCED DIABETIC NEPHROPATHY

Pages

  135-139

Abstract

 DIABETIC NEPHROPATHY (DN) is one of the major causes of end stage renal disease. Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARB) are preferred for delaying progression of DN. This study compared the preventive renal effects of TELMISARTAN (10 mg/kg, p.o.), an ARB, that completely blocks angiotensin action, and BENAZEPRIL (5 mg/kg, p.o.), an ACE inhibitor, which is a partial blocker of angiotensin II production, in an animal model of DIABETIC NEPHROPATHY. DN was induced by streptozotocin (50 mg/kg, i.p.) single injection in male albino rats. Biochemical parameters (creatinine clearance, urinary protein and blood urea) were significantly (p<0.01) altered in diabetic rats after 4 weeks. TELMISARTAN (10 mg/kg, p.o.) and BENAZEPRIL (5 mg/kg, p.o.) treatment significantly (p<0.01) re-duced elevated levels of blood urea and urinary protein in diabetic rats. After 8 weeks of diabetes there was significant difference in reduction of blood urea in between TELMISARTAN and benazeril group. Differ-ence between TELMISARTAN and BENAZEPRIL for reduction in proteinuria was not singnificant. Difference be-tween TELMISARTAN and BENAZEPRIL for creatinine clearance improvement was also not significant (p>0.05). Histology revealed beneficial effects produced by both drugs. This study demonstrates TELMISARTAN is equally renoprotective as BENAZEPRIL.

Cites

  • No record.

    • References

    Cite

    APA: Copy

    SINGH, J., BUDHIRAJA, S., LAL, H., & RANI ARORA, B.. (2006). RENOPROTECTION BY TELMISARTAN VERSUS BENAZEPRIL IN STREPTOZOTOCIN INDUCED DIABETIC NEPHROPATHY. IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT), 5(2), 135-139. SID. https://sid.ir/paper/297126/en

    Vancouver: Copy

    SINGH J., BUDHIRAJA S., LAL H., RANI ARORA B.. RENOPROTECTION BY TELMISARTAN VERSUS BENAZEPRIL IN STREPTOZOTOCIN INDUCED DIABETIC NEPHROPATHY. IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT)[Internet]. 2006;5(2):135-139. Available from: https://sid.ir/paper/297126/en

    IEEE: Copy

    J. SINGH, S. BUDHIRAJA, H. LAL, and B. RANI ARORA, “RENOPROTECTION BY TELMISARTAN VERSUS BENAZEPRIL IN STREPTOZOTOCIN INDUCED DIABETIC NEPHROPATHY,” IRANIAN JOURNAL OF PHARMACOLOGY AND THERAPEUTICS (IJPT), vol. 5, no. 2, pp. 135–139, 2006, [Online]. Available: https://sid.ir/paper/297126/en

    Related Journal Papers

  • No record.

    • Related Seminar Papers

  • No record.

    • Related Plans

  • No record.

    • Recommended Workshops






    Move to top
    telegram sharing button
    whatsapp sharing button
    linkedin sharing button
    twitter sharing button
    email sharing button
    email sharing button
    email sharing button
    sharethis sharing button